chartexchange

Insight Molecular Diagnostics Reports Q3 2026 Revenue of $559,000, GAAP EPS of -$0. ...

GuruFocus | Nov 16, 2026 5:03 PM EST

FDA Review of GraftAssureDx Paused as Company Prepares Response to Additional Information Request Related Stocks: IMDX ,

Read original article